Kohjin Bio Co., Ltd.
JPX: 177A.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Takahito Nakamura
- Employees
- 159
- Headquarters
- Sakado, Japan
- IPO year
- 2024
- Market cap
- ¥7.6B
- Website
- https://www.kohjin-bio.jp
Loading 177A…
Loading profile data…Frequently asked questions about 177A
What does Kohjin Bio Co., Ltd. (177A.T) do?
Kohjin Bio Co., Ltd. manufactures and sells animal blood, sera, tissue culture media, agar media for microorganism tests, in-vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for virus and recombinant protein production, hybridoma, human lymphocyte culture, and insect cell lines; gas permeable cell culture bags an...
Where does 177A.T trade?
Kohjin Bio Co., Ltd. (177A.T) trades on the Tokyo Stock Exchange.
What sector is 177A.T in?
Kohjin Bio Co., Ltd. (177A.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kohjin Bio Co., Ltd.?
Takahito Nakamura is the chief executive officer of Kohjin Bio Co., Ltd. (177A.T).
Where is Kohjin Bio Co., Ltd. headquartered?
Kohjin Bio Co., Ltd. is headquartered in Japan.
Does 177A.T pay a dividend?
Yes — Kohjin Bio Co., Ltd. (177A.T) paid a trailing twelve-month dividend of JPY 10.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 177A.T go public?
Kohjin Bio Co., Ltd. (177A.T) completed its initial public offering in 2024.